QR Code

Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review

BackgroundInfliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor-alpha (TNF-α) that is widely used for induction and maintenance therapy in pediatric inflammatory bowel disease (IBD), yet its effects on the developing intestinal microbiome and treatment response remain uncl...

Full description

Saved in:
Main Authors: Hala Altaher, Mustafa Al-Mashhadani, Rameen Usman, Hardik Ghelani, Reem K. Jan
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2026-07-01
Series:Frontiers in Pharmacology
Subjects:
anti-TNF
dysbiosis
inflammatory bowel disease
infliximab
microbiome
pediatric
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2026.1877033/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items